Brainstorm Cell Therapeutics (BCLI) Competitors $1.18 -0.05 (-3.66%) As of 10:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. RLYB, GBIO, CLNN, CGTX, TENX, CALC, DARE, DRRX, PULM, and GDTCShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Rallybio (RLYB), Generation Bio (GBIO), Clene (CLNN), Cognition Therapeutics (CGTX), Tenax Therapeutics (TENX), CalciMedica (CALC), Daré Bioscience (DARE), DURECT (DRRX), Pulmatrix (PULM), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Rallybio Generation Bio Clene Cognition Therapeutics Tenax Therapeutics CalciMedica Daré Bioscience DURECT Pulmatrix CytoMed Therapeutics Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk. Which has more risk and volatility, BCLI or RLYB? Brainstorm Cell Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.45, meaning that its stock price is 245% less volatile than the S&P 500. Do institutionals & insiders believe in BCLI or RLYB? 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is BCLI or RLYB more profitable? Brainstorm Cell Therapeutics' return on equity of 0.00% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets Brainstorm Cell TherapeuticsN/A N/A -528.56% Rallybio N/A -77.39%-69.33% Do analysts rate BCLI or RLYB? Brainstorm Cell Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 2,431.65%. Rallybio has a consensus price target of $9.75, indicating a potential upside of 1,549.75%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Rallybio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rallybio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the MarketBeat Community believe in BCLI or RLYB? Brainstorm Cell Therapeutics received 247 more outperform votes than Rallybio when rated by MarketBeat users. However, 78.57% of users gave Rallybio an outperform vote while only 59.75% of users gave Brainstorm Cell Therapeutics an outperform vote. CompanyUnderperformOutperformBrainstorm Cell TherapeuticsOutperform Votes29159.75% Underperform Votes19640.25% RallybioOutperform Votes4478.57% Underperform Votes1221.43% Does the media favor BCLI or RLYB? In the previous week, Brainstorm Cell Therapeutics had 9 more articles in the media than Rallybio. MarketBeat recorded 9 mentions for Brainstorm Cell Therapeutics and 0 mentions for Rallybio. Rallybio's average media sentiment score of 0.00 beat Brainstorm Cell Therapeutics' score of -0.18 indicating that Rallybio is being referred to more favorably in the news media. Company Overall Sentiment Brainstorm Cell Therapeutics Neutral Rallybio Neutral Which has preferable earnings & valuation, BCLI or RLYB? Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBrainstorm Cell TherapeuticsN/AN/A-$17.19M-$4.80-0.25Rallybio$636K38.67-$74.56M-$1.35-0.44 SummaryBrainstorm Cell Therapeutics and Rallybio tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.02M$2.98B$5.53B$7.50BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-0.2630.4323.2118.08Price / SalesN/A383.25364.3786.83Price / CashN/A168.6838.1634.64Price / Book-1.033.646.503.99Net Income-$17.19M-$72.06M$3.21B$247.18M7 Day Performance3.36%-9.02%-4.91%-4.25%1 Month Performance-18.22%-16.50%-0.08%-6.87%1 Year Performance-87.85%-31.37%6.54%-3.73% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics3.5835 of 5 stars$1.19-3.7%$30.00+2,431.6%-88.1%$6.76MN/A-0.2540Earnings ReportUpcoming EarningsAnalyst ForecastRLYBRallybio1.7902 of 5 stars$0.65+2.2%$9.75+1,389.7%-66.6%$27.24M$636,000.00-0.4140Gap DownGBIOGeneration Bio3.6728 of 5 stars$0.41-5.3%$7.33+1,710.7%-90.4%$27.14M$19.89M-0.18150Gap DownCLNNClene3.251 of 5 stars$3.08-4.3%$55.25+1,693.8%-62.5%$26.45M$342,000.00-0.58100Gap DownCGTXCognition Therapeutics3.6388 of 5 stars$0.42+1.2%$7.13+1,593.2%-80.4%$26.08MN/A-0.4320Gap DownTENXTenax Therapeutics1.6764 of 5 stars$6.55+0.9%$18.00+174.8%+46.0%$25.97MN/A-1.239Gap DownCALCCalciMedica2.3593 of 5 stars$1.91-4.0%$18.00+842.4%-56.7%$25.75MN/A-1.7730Analyst ForecastAnalyst RevisionNews CoverageDAREDaré Bioscience1.5094 of 5 stars$2.89+0.3%$24.00+730.4%-49.3%$25.14M$1.88M-4.8930Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionDRRXDURECT0.4124 of 5 stars$0.80+0.3%$5.00+523.4%-30.5%$24.90M$8.59M-1.3180Analyst ForecastPULMPulmatrix0.0578 of 5 stars$6.66-7.4%N/A+229.3%$24.31M$7.81M-2.5220News CoverageGap DownGDTCCytoMed Therapeutics2.0367 of 5 stars$2.20-2.2%$5.00+127.3%+13.7%$24.07MN/A0.00N/APositive News Remove Ads Related Companies and Tools Related Companies RLYB Competitors GBIO Competitors CLNN Competitors CGTX Competitors TENX Competitors CALC Competitors DARE Competitors DRRX Competitors PULM Competitors GDTC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCLI Stock Free BCLI Stock Alerts